Catalyst Wire Dossier Catalyst Wire Dossier

inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)

· CanSino Biologics Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), covering 2023-06-18 to 2023-06-18. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) [Phase 3]

See pricing